| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11883-006-0034-8 |
| P698 | PubMed publication ID | 16901407 |
| P50 | author | Christie M. Ballantyne | Q98665268 |
| P2093 | author name string | Vijay Nambi | |
| P2860 | cites work | Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association | Q22241929 |
| The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma | Q24540170 | ||
| Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase | Q24562119 | ||
| The effect of statin therapy on lipoprotein associated phospholipase A2 levels | Q28181900 | ||
| Platelet-activating Factor Acetylhydrolases | Q28243333 | ||
| The expanding superfamily of phospholipase A(2) enzymes: classification and characterization | Q28609761 | ||
| Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis | Q33567912 | ||
| Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. | Q34183376 | ||
| A mutation in plasma platelet-activating factor acetylhydrolase (Val279-->Phe) is a genetic risk factor for stroke | Q34450657 | ||
| Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. | Q34457192 | ||
| Phospholipase A2. | Q34548389 | ||
| Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease | Q35178997 | ||
| SB-480848. GlaxoSmithKline. | Q35745409 | ||
| Lipoprotein-associated phospholipase A2 as a target of therapy | Q36180406 | ||
| Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke | Q36269180 | ||
| Involvement of PAF in atherogenesis. Brief review | Q36328940 | ||
| Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target | Q36403910 | ||
| Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress | Q40332526 | ||
| Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern G | Q40479587 | ||
| A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women | Q40678229 | ||
| Activation of ICAM-1 promoter by lysophosphatidylcholine: possible involvement of protein tyrosine kinases | Q41121082 | ||
| Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor | Q42992999 | ||
| Lipoprotein-associated PLA2 inhibition--a novel, non-lipid lowering strategy for atherosclerosis therapy | Q43604021 | ||
| Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages. | Q43750480 | ||
| N-linked glycosylation of macrophage-derived PAF-AH is a major determinant of enzyme association with plasma HDL. | Q43759106 | ||
| Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. | Q43880589 | ||
| Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles | Q44238552 | ||
| Electronegative LDL of FH subjects: chemical characterization and induction of chemokine release from human endothelial cells. | Q44283323 | ||
| Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. | Q44336589 | ||
| The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2. | Q44366566 | ||
| Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe | Q44474837 | ||
| Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study | Q44752425 | ||
| Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes | Q44786953 | ||
| Relation of markers of inflammation (C-reactive protein, white blood cell count, and lipoprotein-associated phospholipase A2) to the ankle-brachial index. | Q44882278 | ||
| Effects of antihypertensive and hypolipidemic drugs on plasma and high-density lipoprotein-associated platelet activating factor-acetylhydrolase activity. | Q45016944 | ||
| Platelet-activating factor acetylhydrolase is not associated with carotid intima-media thickness in hypercholesterolemic Sicilian individuals | Q45057084 | ||
| Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study | Q45119500 | ||
| Increased lysophosphatidylcholine and non-esterified fatty acid content in LDL induces chemokine release in endothelial cells. Relationship with electronegative LDL. | Q45142360 | ||
| Impaired binding affinity of electronegative low-density lipoprotein (LDL) to the LDL receptor is related to nonesterified fatty acids and lysophosphatidylcholine content | Q45185008 | ||
| Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up | Q45200533 | ||
| Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study | Q45256250 | ||
| Reduction in the extent of atherosclerosis in apolipoprotein E-deficient mice induced by electroporation-mediated transfer of the human plasma platelet-activating factor acetylhydrolase gene into skeletal muscle | Q45856333 | ||
| LDL- is a lipid hydroperoxide-enriched circulating lipoprotein. | Q46430533 | ||
| Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects | Q46447584 | ||
| Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia. | Q46634215 | ||
| Biochemical and cytotoxic characteristics of an in vivo circulating oxidized low density lipoprotein (LDL-). | Q46745439 | ||
| Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study | Q46825104 | ||
| Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study | Q46864783 | ||
| Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infar | Q46990506 | ||
| Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment. | Q51571771 | ||
| The effect of including C-reactive protein in cardiovascular risk prediction models for women. | Q51797108 | ||
| L5, the most electronegative subfraction of plasma LDL, induces endothelial vascular cell adhesion molecule 1 and CXC chemokines, which mediate mononuclear leukocyte adhesion. | Q53749030 | ||
| Association between Lp-PLA2 and coronary artery disease: Focus on its relationship with lipoproteins and markers of inflammation and hemostasis | Q57192508 | ||
| Molecular Basis of the Interaction between Plasma Platelet-activating Factor Acetylhydrolase and Low Density Lipoprotein | Q63579199 | ||
| Platelet-Activating Factor Acetylhydrolase Is Mainly Associated With Electronegative Low-Density Lipoprotein Subfraction | Q64355663 | ||
| Platelet-activating factor acetylhydrolase increases during macrophage differentiation. A novel mechanism that regulates accumulation of platelet-activating factor | Q69612982 | ||
| Human platelets release a paf-acether: acetylhydrolase similar to that in plasma | Q70638656 | ||
| Lysophosphatidylcholine stimulates the expression and production of MCP-1 by human vascular endothelial cells | Q71061251 | ||
| A cytotoxic electronegative LDL subfraction is present in human plasma | Q71101450 | ||
| PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme | Q71799184 | ||
| Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group | Q73088406 | ||
| Isolation, Characterization, and Functional Assessment of Oxidatively Modified Subfractions of Circulating Low-Density Lipoproteins | Q73256291 | ||
| Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis | Q73350111 | ||
| Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease | Q73901926 | ||
| Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in japan | Q74080872 | ||
| Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice | Q77763890 | ||
| Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma | Q78056182 | ||
| Ischemia aggravating effects of platelet-activating factor in acute myocardial ischemia | Q93607967 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 374-381 | |
| P577 | publication date | 2006-09-01 | |
| P1433 | published in | Current Atherosclerosis Reports | Q20821076 |
| P1476 | title | Lipoprotein-associated phospholipase A2: pathogenic mechanisms and clinical utility for predicting cardiovascular events | |
| P478 | volume | 8 |
| Q37285933 | Lipoprotein(a): a promising marker for residual cardiovascular risk assessment |
| Q37738359 | Recent developments with lipoprotein-associated phospholipase A2 inhibitors |
| Q37690826 | Role of secretory phospholipase A₂ in women with metabolic syndrome |
| Q36945209 | The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis |
Search more.